ジェネゼンとオプティウム、cGMP製造支援で提携

ウイルスベクターの開発・製造受託機関（CDMO）のリーディングカンパニーであるジェネゼンと、革新的なCAR-T細胞療法の発見と開発に取り組む前臨床段階の企業であるオプティウム・バイオテクノロジーズ社（Optieum Biotechnologies, Inc.

Derived from Optieum’s proprietary Eumbody System, OPTF01 specifically targets Fibroblast activation protein-alpha (FAPα), a protein expressed on both tumor cells and the surrounding pericytes and Cancer-associated Fibroblasts (CAFs). Hence, OPTF01 can potentially disrupt the immunosuppressive microenvironment around the tumor while simultaneously attacking the malignant cells within the tumor. Successful development of this therapeutic approach would address a critical unmet medical need for patients with refractory glioblastoma who currently face limited treatment options with poor prognoses, as well as various other solid tumor indications.

Under this collaboration, Genezen will provide the technology transfer, process development, and cGMP manufacturing of the LVV construct used in the onward production of the OPTF01 CAR-T product. “Genezen is honored to support Optieum’s best-in-class CAR-T programs with our best-in-class LVV expertise to bring these critical therapies to life,” said スティーブ・ファヴァロロ, Chairman and CEO of Genezen. “This collaboration with Optieum underscores our rich experience and the capabilities of both our people and state-of-the-art facilities to support customers on a global scale – now including a leading Japanese biotech.”

- 広告

こちらもお読みください： パース・バイオサイエンス社が日本の販売代理店スクラム社と提携

西岡 俊のCEO。 オプティウム added, “At Optieum, we are committed to redefining the future of CAR-T therapy through relentless innovation and scientific rigor. Partnering with ジェネゼン‘s team of experts ensures that critical materials for our groundbreaking therapies are manufactured to the highest standards, accelerating our progress toward delivering next-generation therapies for glioblastoma and other solid tumors.”

OPTF01は、CAR-T細胞療法開発において大きな進歩を遂げた独自のプラットフォームであるEumbodyシステムから生まれました。このプラットフォームは、迅速かつ広範な機能スクリーニングを活用し、これまでにない方法でCARコンストラクトを同定・最適化します。一本鎖可変フラグメント（scFv）配列を動的に調和させてT細胞の機能的能力を高めることにより、EumbodyシステムはCAR-T技術革新の新たな基準を打ち立てます。

ソース PRNewsWire